Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sale, and wholesaling of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally. The company offers pharmaceutical products for cardiology, chronic pain and oncology, central nervous system, respiratory system, gastrointestinal system, and urology; and over the counter (OTC) drugs, such as antiseptics, anagelsics, and anti-lice treatment products. It also provides a range of skincare products focused on health. The company was founded in 1911 and is based in Paiania, Greece.
Frequently asked questions
What sector does Lavipharm S.A (LAVI) operate in?
Lavipharm S.A belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Lavipharm S.A (LAVI) current stock price?
As of the latest data, Lavipharm S.A stock price is €1.56, with a previous close of €1.56.
What is Lavipharm S.A (LAVI) current market capitalization?
Lavipharm S.A market cap is approximately 266.41 million.
What is Lavipharm S.A (LAVI) Earnings Per Share (EPS)?
The trailing EPS is €0.03.
What is Lavipharm S.A (LAVI) Price-to-Earnings (P/E) ratio?
Lavipharm S.A current P/E ratio is 52.
Does Lavipharm S.A (LAVI) pay dividends?
Yes. Lavipharm S.A pays annual dividends with an annualized yield of 1.28% and an estimated annual payout of €0.02 per share.
When is the next ex-dividend date for Lavipharm S.A (LAVI)?
The next ex-dividend date is scheduled for July 20, 2027.
What is Lavipharm S.A (LAVI) beta (volatility) score?
Lavipharm S.A has a beta of 1.000, meaning its volatility is roughly in line with the market.
